Iloperidone
ApprovedRecruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia, Bipolar I Disorder
Trial Timeline
May 24, 2023 → Nov 30, 2026
NCT ID
NCT05648591About Iloperidone
Iloperidone is a approved stage product being developed by Vanda Pharmaceuticals for Schizophrenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05648591. Target conditions include Schizophrenia, Bipolar I Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05648591 | Approved | Recruiting |
| NCT05344365 | Phase 2 | Withdrawn |
| NCT04712734 | Phase 1 | Completed |
| NCT04127058 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia